Addiction
Do GLP-1 drugs lower AUD hospitalizations?
Open access · cc by · source: Europe PMC
In 227,866 Swedes with AUD, semaglutide (aHR 0.64) and liraglutide (aHR 0.72) use periods had lower AUD hospitalization risk than nonuse—stronger than approved AUD meds overall.
Study at a glance
- Design
- Cohort — Swedish register cohort with within-individual Cox models of GLP-1 agonist exposure
- N
- N=227866 · Residents aged 16–64 with AUD diagnosis; GLP-1 users are a subset
- Population
- Nationwide Swedish individuals with alcohol use disorder (2006–2023 follow-up)
- Outcome
- Hospitalization for AUD (primary); SUD, somatic hospitalization, suicide attempt (secondary)
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Semaglutide and liraglutide showed the largest AUD/SUD hospitalization risk reductions; any AUD medication only aHR ~0.98; somatic hospitalizations also lower; suicide attempts not clearly changed.
Methodology
Built drug-use periods from registers and ran within-individual Cox models comparing GLP-1 agonist use vs nonuse and AUD medications vs nonuse.
Limitations
Randomized efficacy in AUD without diabetes/obesity indication, or that all GLP-1 agonists are equal.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Semaglutide/liraglutide are being explored beyond glycemic control (e.g., alcohol use disorder).
Repurposing work examines semaglutide and liraglutide for alcohol use disorder—illustrating that receptor class claims travel across indications carefully.
Evidence for the claim as stated.
Related papers in this topic
Same topic cluster — not a recommendation engine.